Acne research funding gaps mean that crucial treatment advances are being delayed or sidelined entirely, leaving millions of patients with limited options for conditions we don’t fully understand. While the global acne treatment market is valued at $13.44 billion as of 2023 and expected to reach $23.33 billion by 2034, the investment in fundamental research about acne’s root causes remains disproportionately small compared to the scale of the problem—acne affects up to 50 million Americans annually, making it the most prevalent illness in the United States. This article explores how inadequate funding in specific research areas is creating bottlenecks in treatment progress, which areas are being neglected, and what emerging trials reveal about the future of acne care when resources are focused strategically.
The disconnect between market size and research depth reveals a troubling pattern: the acne treatment industry invests heavily in incremental improvements to existing solutions while fundamental questions go unanswered. For example, we still lack comprehensive, globally standardized epidemiological data about acne burden and disparities across populations, which limits our ability to develop targeted treatments for underserved communities. Skin disease advocacy organizations have sponsored over $50 million in grants to support young scientists in dermatology research, but much of this funding flows toward narrow applications rather than the foundational science that could reshape how we prevent and treat acne entirely.
Table of Contents
- Where Are the Biggest Research Funding Gaps in Acne Treatment?
- The Market-Research Mismatch: Why Funding Doesn’t Follow Disease Burden
- What Recent Clinical Trials Reveal About Strategic Funding Priorities
- Which Patient Populations Are Being Left Behind by Research Funding Gaps?
- The Antibiotic Resistance Crisis Hiding in Acne Research Funding Failures
- Emerging Treatments as a Window Into Funding Priorities
- Redirecting Research Priorities for Treatment Progress
- Conclusion
- Frequently Asked Questions
Where Are the Biggest Research Funding Gaps in Acne Treatment?
The most glaring gaps exist in areas that require long-term, foundational research without immediate commercial payoff. Pollution’s impact on acne remains insufficiently studied despite decades of anecdotal evidence that air quality affects skin, and the precise role of dietary factors beyond high glycemic load and dairy consumption is still unclear. Gene-environment interactions—how individual genetic susceptibility interacts with lifestyle, environment, and diet—represent another nearly untouched frontier. These topics don’t attract the same venture capital interest as targeted drug development because the research timelines are longer and the commercialization path less obvious.
The consequences of these gaps are concrete. A 25-year-old woman with acne in an urban environment where air pollution is severe may have her condition exacerbated by factors we can’t yet quantify or address, simply because no one has funded large-scale studies examining this relationship. Similarly, the hormonal treatment landscape for acne in women remains underutilized; spironolactone and oral contraceptives could reduce long-term antibiotic use significantly, yet these approaches aren’t studied or promoted with the same intensity as newer oral medications entering clinical trials. This represents a missed opportunity to improve outcomes for a population already affected by acne at rates comparable to or exceeding those in men.
The Market-Research Mismatch: Why Funding Doesn’t Follow Disease Burden
A paradox exists in acne research funding: the disease burden is enormous, yet the research investment in prevention and foundational understanding is modest relative to market activity. The acne treatment market is expanding at a 5.14% compound annual growth rate through 2034, driven primarily by demand for new prescription therapies, dermatological procedures, and over-the-counter products. However, this market growth reflects demand for solutions to a problem, not necessarily investment in understanding the problem itself.
This creates a structural bias toward drug development and away from epidemiological research, lifestyle factors, and preventive approaches. The NIH funds research on acne pathophysiology, isotretinoin safety, and antibiotic resistance through skin Disease Research Centers, and the Medical Research Council has supported adolescent acne research in populations like those in urban South Africa and post-HIV care settings, but these efforts are islands in a much larger ocean of unmet research needs. The gap becomes apparent when you consider that steady increases in acne incidence, prevalence, and disability-adjusted life-years were reported at the 2025 Society for Investigative Dermatology Annual Meeting, yet the funding mechanisms to understand why these trends are accelerating remain fragmented and underfunded.
What Recent Clinical Trials Reveal About Strategic Funding Priorities
When funding does concentrate on specific research areas, the results can be striking. Dermata Therapeutics’ Phase 3 STAR-1 trial met all three primary endpoints in March 2025 for moderate-to-severe acne treatment, demonstrating highly statistically significant results versus placebo—a clear win in the pursuit of new therapeutic options. Similarly, Denifanstat (ASC40) Phase 3 trials showed a 60% reduction in total acne lesions with minimal adverse effects, positioning oral treatments as potential alternatives to current standards of care.
These advances are important, but they highlight an uncomfortable truth: when companies have funding to run large, rigorous Phase 3 trials, results emerge. Biofrontera completed Phase 2b trials for Ameluz with topline data anticipated for early 2026, and Sanofi has a Phase 1 clinical study planned for Q2 2025 to evaluate their new acne treatment approach. The pipeline shows movement on drug development, yet most of this funding targets symptom management and lesion reduction rather than the underlying causes that create acne in the first place. A 30-year-old patient struggling with persistent acne despite multiple treatments might benefit more from research into why their immune system overreacts to Cutibacterium acnes, but that type of foundational research attracts far less funding than Phase 3 trials for new topicals.
Which Patient Populations Are Being Left Behind by Research Funding Gaps?
Notable disparities exist in acne research by sex and geographic location, a reality underscored by recent epidemiological data. Women in particular face gaps in hormonal acne research; while oral contraceptives and spironolactone are well-established tools, the research supporting their use as first-line treatments for women with acne remains comparatively limited compared to studies of topical retinoids and antibiotics. This leaves many dermatologists and patients uncertain about when and how to optimize hormonal therapies.
Geographic disparities are equally troubling. The Medical Research Council’s funding for adolescent acne research in populations like those in South Africa and post-HIV care settings reveals that these communities are recognized as research priorities, yet funding remains episodic rather than sustained. A teenager with acne in sub-Saharan Africa may lack access not only to current treatments but also to dermatological research that reflects their specific population’s biology and environmental factors. The absence of globally standardized epidemiological data means we cannot even quantify these disparities precisely, let alone prioritize resources to address them.
The Antibiotic Resistance Crisis Hiding in Acne Research Funding Failures
One of the most consequential funding gaps involves antibiotic resistance in acne treatment. Acne is one of the most common reasons antibiotics are prescribed to adolescents and young adults, yet research into stewardship—how to use these antibiotics more judiciously and for shorter durations—has historically underfunded compared to developing new topical or oral alternatives. The NIH recognizes antibiotic resistance as a research priority through its Skin Disease Research Centers, but this focus came late, after decades of prescribing patterns had already contributed to rising resistance rates.
This gap has real consequences. A 16-year-old prescribed doxycycline for acne is contributing to a resistance problem that could compromise the antibiotic’s effectiveness not only for their acne but for other infections throughout their lifetime. Yet research into when antibiotics are truly necessary, which populations benefit most from alternative approaches, and how to transition patients off long-term antibiotic therapy remains fragmented across academic institutions with limited coordinated funding. Strategies like combining antibiotics with benzoyl peroxide to slow resistance, or prioritizing retinoid-based regimens from the outset, need more robust evidence bases—evidence that sustained research funding could provide.
Emerging Treatments as a Window Into Funding Priorities
The recent surge in Phase 3 trial results—from Dermata, Ascletis, Biofrontera, and Sanofi—reveals where private and public funding are converging: on novel mechanisms that offer alternatives to current standards. Dermata’s success with their approach, Denifanstat’s 60% lesion reduction, and Ameluz’s progression through trials all suggest that when funding aligns behind specific therapeutic hypotheses, the science moves forward.
These successes matter for patients with moderate-to-severe acne who have exhausted or cannot tolerate current options. However, these advances also highlight what isn’t being funded: research into why these new mechanisms work better for some patients than others, how to predict treatment response, and how to develop true preventive therapies that could reduce acne incidence before it becomes moderate-to-severe. A patient who could have been spared years of acne through a preventive intervention identified in their adolescence would benefit far more than one who receives a new treatment at age 25, yet prevention research remains perpetually underfunded.
Redirecting Research Priorities for Treatment Progress
The path forward requires a deliberate reorientation of research funding toward the gaps that matter most. Sustained, coordinated funding for gene-environment interaction studies could unlock why some individuals develop acne while others don’t despite similar environmental exposures. Investment in standardized, global epidemiological research would provide the evidence base for targeted interventions in underserved populations.
Expanded research into hormonal mechanisms and optimization of spironolactone and oral contraceptive use could transform outcomes for women with acne while simultaneously reducing unnecessary antibiotic prescribing. The good news is that the infrastructure exists: skin disease advocacy organizations, the NIH, and the Medical Research Council have demonstrated willingness to fund acne research. What’s needed is a shift in emphasis—allocating more resources to foundational questions, population disparities, and prevention while continuing to support the incremental advances in treatment that the market is already incentivizing. The next 5-10 years will reveal whether the acne research community can close these gaps or whether the market-driven funding model will continue to dominate, leaving millions of patients waiting for answers to basic questions about their condition.
Conclusion
The path forward requires a deliberate reorientation of research funding toward the gaps that matter most. Sustained, coordinated funding for gene-environment interaction studies could unlock why some individuals develop acne while others don’t despite similar environmental exposures. Investment in standardized, global epidemiological research would provide the evidence base for targeted interventions in underserved populations.
Expanded research into hormonal mechanisms and optimization of spironolactone and oral contraceptive use could transform outcomes for women with acne while simultaneously reducing unnecessary antibiotic prescribing. The good news is that the infrastructure exists: skin disease advocacy organizations, the NIH, and the Medical Research Council have demonstrated willingness to fund acne research. What’s needed is a shift in emphasis—allocating more resources to foundational questions, population disparities, and prevention while continuing to support the incremental advances in treatment that the market is already incentivizing. The next 5-10 years will reveal whether the acne research community can close these gaps or whether the market-driven funding model will continue to dominate, leaving millions of patients waiting for answers to basic questions about their condition.
Frequently Asked Questions
Why isn’t there more research funding for acne prevention?
Prevention research offers no near-term commercial opportunity and requires long-term, population-level studies. Pharmaceutical companies and venture capital focus on treatable cases, while preventive research depends on government funding that has historically prioritized other dermatological conditions. This creates a structural incentive toward treatment rather than prevention.
How do funding gaps affect antibiotic resistance in acne treatment?
Decades of liberal antibiotic prescribing for acne went largely unexamined because antibiotic stewardship research received minimal funding compared to new drug development. As a result, resistance rose without corresponding investment in alternatives or deprescribing strategies. The NIH now recognizes this as a priority, but the gap has already created public health consequences.
Are there any acne research areas where funding is adequate?
Phase 3 clinical trials for novel therapeutic mechanisms are well-funded, as evidenced by recent successes from Dermata, Denifanstat, and Biofrontera. Drug development remains the best-resourced area. Foundational research into acne pathophysiology and population-specific factors lag significantly behind.
How do research funding gaps affect patients with acne?
Gaps mean patients may have limited knowledge about prevention, fewer evidence-based alternatives to antibiotics and retinoids, and less tailored treatment based on their specific biology or environment. Underserved populations experience these gaps most acutely due to limited research specific to their needs.
What would a better-funded acne research landscape look like?
Coordinated, long-term funding for epidemiological studies, gene-environment interaction research, hormonal therapy optimization, and prevention science alongside continued development of new treatments. This would require sustained government and foundation investment beyond what the market incentivizes.
